GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Terns Pharmaceuticals Inc (NAS:TERN) » Definitions » Earnings per Share (Diluted)

Terns Pharmaceuticals (Terns Pharmaceuticals) Earnings per Share (Diluted) : $-1.27 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Terns Pharmaceuticals Earnings per Share (Diluted)?

Terns Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.29. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.27.

Terns Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2023 was $-0.29. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.27.

Terns Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-0.29. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.27.

During the past 3 years, the average EPS without NRIGrowth Rate was 10.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -3.80% per year.

During the past 6 years, Terns Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 16.40% per year. The lowest was -44.10% per year. And the median was 10.40% per year.


Terns Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Terns Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terns Pharmaceuticals Earnings per Share (Diluted) Chart

Terns Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial -2.86 -1.29 -2.21 -1.67 -1.27

Terns Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.31 -0.25 -0.42 -0.29

Competitive Comparison of Terns Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Terns Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Terns Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Terns Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Terns Pharmaceuticals's PE Ratio falls into.



Terns Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Terns Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-90.21-0)/71.259
=-1.27

Terns Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-21.019-0)/72.345
=-0.29

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Terns Pharmaceuticals  (NAS:TERN) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Terns Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Terns Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Terns Pharmaceuticals (Terns Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
Executives
Mark J. Vignola officer: Chief Financial Officer C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Seokho Bryan Yoon officer: COO and General Counsel NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram director, officer: Chief Executive Officer NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Hongbo Lu director C/O AVEDRO, INC., 201 JONES ROAD, WALTHAM MA 02451
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Lav Biosciences Fund V, L.p. 10 percent owner C/O ESTERA TRUST (CAYMAN) LIMITED, 75 FORT STREET, PO BOX 1350, GRAND CAYMAN E9 KY1-1108
Lav Aqua Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Hopewell Resources Holdings Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Oriental Spring Venture Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Orbimed Capital Gp Vii Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Iii Ltd director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Asia Gp Iii, L.p. director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629